Clinical trial · no report yet · Phase 1

PrE0807

Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

NCT03532451 ↗
Completed
PrECOG, LLC.
Focused

We haven't built an HCP commentary report on PrE0807 (nivolumab plus lirilumab; nivolumab in cisplatin-ineligible muscle-invasive bladder cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Indexed commentary on PrE0807 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

Channel	Indexed
X threads	3

Indexed todayTypical once built

The trial

ClinicalTrials.gov

Official title: Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
Phase: Phase 1
Status: Completed
Conditions: Bladder Cancer
Interventions: Nivolumab; Nivolumab/Lirilumab
Arms: Cohort 1: Nivolumab · Experimental
Cohort 2: Nivolumab/Lirilumab · Experimental
Enrollment: 43
Primary outcomes: Grade 3 or Higher Treatment Related Adverse Events as Assessed by CTCAE V5.0
Sponsor: PrECOG, LLC. with Bristol-Myers Squibb
Start: Mar 22, 2019
Primary completion: Nov 27, 2020
Results posted: Yes
Registry record: NCT03532451 · updated Sep 19, 2024

Publications

linked from the registry

Grivas P, Koshkin VS, Chu X, Cole S, Jain RK, Dreicer R, Cetnar JP, Sundi D, Gartrell BA, Galsky MD, Woo B, Li-Ning-Tapia E, Hahn NM, Carducci MA. PrECOG PrE0807: A Phase 1b Feasibility Trial of Neoadjuvant Nivolumab Without and with Lirilumab in Patients with Muscle-invasive Bladder Cancer Ineligible for or Refusing Cisplatin-based Neoadjuvant Chemotherapy. Eur Urol Oncol. 2024 Aug;7(4):914-922. doi: 10.1016/j.euo.2023.11.022. Epub 2023 Dec 27. PubMed 38155060